title: Pulmonary exacerbations in CF patients with early lung disease.
abstract: BACKGROUND
  Current definitions of pulmonary exacerbation (PE) in cystic fibrosis are based on studies in participants with significant lung disease and may not reflect the spectrum of findings observed in younger patients with early lung disease.
  
  
  METHODS
  We used data from a recent trial assessing the efficacy of azithromycin in children to study signs and symptoms associated with PEs and related changes in lung function and weight.
  
  
  RESULTS
  While increased cough was present in all PEs, acute weight loss and reduction in oxygen saturation were not observed. Changes in lung function did not differ between subjects who did experience a PE and those who were exacerbation-free.
  
  
  CONCLUSIONS
  Cough was the predominant symptom in CF patients with early lung disease experiencing a PE. There was no significant difference in mean 6-month change in lung function or weight among subjects with one or more exacerbations and those without an exacerbation.
authors.affiliation: Kentucky Children's Hospital, University of Kentucky, Lexington, KY United States. Electronic address: mianst0@uky.edu.
authors.forename: Michael
authors.initials: M
authors.lastname: Anstead
authors.affiliation: Department of Pediatrics, Columbia University, New York, NY, United States.
authors.forename: Lisa
authors.initials: L
authors.lastname: Saiman
authors.affiliation: University of Washington, Seattle, WA, United States.
authors.forename: Nicole
authors.initials: N
authors.lastname: Mayer-Hamblett
authors.affiliation: Department of Pediatrics, McGill University, Montreal, Canada.
authors.forename: Larry C
authors.initials: LC
authors.lastname: Lands
authors.affiliation: University of Washington, Seattle, WA, United States.
authors.forename: Margaret
authors.initials: M
authors.lastname: Kloster
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA, United States.
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Goss
authors.affiliation: Cystic Fibrosis Therapeutics Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States.
authors.forename: Lynn
authors.initials: L
authors.lastname: Rose
authors.affiliation: Division of Infectious Diseases, Seattle Children's Hospital, Seattle, WA, United States.
authors.forename: Jane L
authors.initials: JL
authors.lastname: Burns
authors.affiliation: Cystic Fibrosis Foundation, Bethesda, DC, United States.
authors.forename: Bruce
authors.initials: B
authors.lastname: Marshall
authors.affiliation: Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada; Program in Physiology and Experimental Medicine, SickKids Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
authors.forename: Felix
authors.initials: F
authors.lastname: Ratjen
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D002648:Child; D003371:Cough / Q000188:drug therapy / Q000503:physiopathology; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008168:Lung / Q000473:pathology / Q000503:physiopathology; D008171:Lung Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin
keywords: Azithromycin; Chronic; Cystic fibrosis; Infection; Lung function; Mild; Pseudomonas aeruginosa; Pulmonary exacerbation; Weight